The original disclosure in Japanese was released on January 30, 2018
Consolidated Financial Statements for the Third Quarter Ended December 31, 2017
FY2017 (April 1, 2017 - March 31, 2018)
Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
http://www.takara-bio.co.jp
Koichi Nakao, President
Shuichiro Matsuzaki, Executive Vice President
Tel. (077) 565-6970
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
1. Results for the three months ended December 31, 2017 (April 1, 2017 – December 31, 2018)(1) Operating results(Percentages indicate changes from the same period of the previous fiscal year.)Nine months ended
December 31, 2017
Net sales
Operating income
Ordinary income
Net income (loss) attributable to owners of theparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
Note: Comprehensive income(Millions of yen)
22,646
1,608
1,762
1,068

Nine months endedDecember 31, 2016
(%)

(%)

9.7(41.0)(38.6)(31.5)(Millions of yen)
20,6452,724
2,869
1,561(0.3)
88.6
69.0
154.4

-

12.97
(1,482)

-

8.88
881

(2) Financial position
As of December 31, 2017
(Millions of yen)

As of March 31, 2017
(Millions of yen)

66,75960,31590.2
500.0760,216

67,14359,98589.2
497.32
59,884

Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity
2. Dividends

First quarter end
Second quarter end
Third quarter end
Year end
AnnualAnnual dividends per share in yen
Year ended March 31,
Year ended March 31,
Year ending March 31,
2017
2018
2018(Forecast)
4.00
4.00
4.00
4.00

3. Forecast for the year ending March 31, 2018 (April 1, 2017 – March 31, 2018)(Percentages indicated changes from the same period of the previous fiscal year.)Year ending March 31, 2018
(Millions of yen)(%)
Net sales
Operating income
Ordinary income
Net income attributable to owners of the parent
Net income attributable to owners of the parent per share (in yen)
Note: Correction of financial forecast from the most recent financial forecast : No- 1 -33,000
3,500
3,800
2,000
16.61

12.3
9.3
6.2
47.9

4. Others(1) Material changes in subsidiaries during this period(Changes in scope of consolidations resulting from change in subsidiaries) ： Yes
Newly include：2 (Name) Rubicon Genomics, Inc., WaferGen Bio-systems, Inc.
Excluded：2 (Name) Rubicon Genomics, Inc., WaferGen Bio-systems, Inc.
(2) Applying of specific accounting of the consolidated quarterly financial statements ： No
(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement1) Changes based on revisions of accounting standard： No
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No(4) Number of outstanding shares (common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
As of December 31, 2017：
120,415,600
120,415,600
As of March 31, 2017：2) Number of treasury stocks at year end
As of December 31, 2017：
As of March 31, 2017：
3) Average number of outstanding shares
As of December 31, 2017：
120,415,600
120,415,600
As of March 31, 2017：- 2 -